Skip to main content

L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors

Buy Article:

$43.00 plus tax (Refund Policy)

Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn M-J, Lee J, Kim Y, Cui ZY, Hong HJ, Kim J-M, Li S, Hwang IG, Park K. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS 2009; 117: 140–6.

Pulmonary neuroendocrine tumors are a distinct subset of neoplasms with indolent to aggressive behavior. This study was conducted to evaluate the prognostic role of L1 cell adhesion molecule (L1CAM) in pulmonary neuroendocrine tumors. We retrospectively analyzed L1 expression in 55 cases of completely resected carcinoids and large-cell neuroendocrine carcinomas, by the immunohistochemistry with monoclonal antibody A10-A3 against human L1. L1 immunoreactivity was detected in 34 (61.8%) of 55 specimens. There was a significant correlation between L1 expression and the World Health Organization classification of this tumor (Spearman rank correlation, =0.60, p<0.001). With median follow-up of 52.0 months, the 5-year survival rate for patients with low expression of L1 (<20% of tumor cells stained) was significantly better compared with those with high expression of L1 (82.6% vs. 43.7%, p=0.005). L1 was also a significant independent predictor of disease-free survival, and patients with high L1 expression have a higher risk for recurrence compared with those with low L1 expression (hazard ratio, 3.0; 95% confidence interval, 1.2–8.3; p=0.034). L1 expression is significantly associated with aggressiveness and further studies with larger samples are needed to validate potential prognostic value for pulmonary neuroendocrine tumors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: L1; cell adhesion molecules; lung; neuroendocrine tumors

Document Type: Research Article

Affiliations: 1: Samsung Medical Center, Division of Hematology–Oncology, Sungkyunkwan University School of Medicine, Seoul; 2: Medical Nanoelement Development Center, Samsung Bio Institute, Seoul; 3: Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; 4: Department of Pathology and Cancer Research Institute, Chungnam National University School of Medicine, Daejeon; 5: Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul; and 6: Department of Medicine, Division of Hematology–Oncology, Chung-Ang University Yong-San Hospital, Seoul, Korea

Publication date: 01 February 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more